IMC Chicago’s Summit Therapeutics SMMT Stock Holding History

IMC Chicago’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-29,704	Closed	-$480K	–	5943
2025 Q4	$520K	Buy	+29,704	New	+$559K	﹤0.01%	3449

Other funds holding SMMT

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

ACL

APEIRON Capital Ltd Hong Kong $156M AUM 183.17% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

HWM

Hohimer Wealth Management Seattle, Washington $1B AUM 33.02% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

IMC Chicago's SMMT Position: Q1 2026 in Review

IMC Chicago sold out of Summit Therapeutics (SMMT) in Q1 2026, closing a stake of 29,704 shares — an estimated $480K sold.

IMC Chicago first reported a position in SMMT in Q4 2025 and held it in 1 quarter. The position peaked at $520K in Q4 2025. 222 funds tracked by Wall St. Rank hold SMMT as of Q1 2026.

IMC Chicago reported no remaining Summit Therapeutics position as of Q1 2026 after selling out during the quarter.
IMC Chicago sold 29,704 Summit Therapeutics shares in Q1 2026, an estimated $480K.
IMC Chicago first reported a position in Summit Therapeutics in Q4 2025 and held it in 1 quarter.
IMC Chicago's Summit Therapeutics position peaked at $520K in Q4 2025.
222 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2026.

Based on IMC Chicago's 13F filing for Q1 2026, filed 5 May 2026.